Skip to main content

Table 5 Reports of adverse reactions determined by abnormal laboratory data

From: A laboratory data-based evaluation of the efficacy and safety of generic pravastatin sodium for long-term use

Age (years) Sex Treatment duration (weeks) Adverse reaction CTCAE Grade
70 Female 16 Increased CPK 200 IU/L I
66 Female 10 Increased CPK 219 IU/L I
67 Female 40 Increased CPK 189 IU/L I
68 Female 15 Increased CPK 200 IU/L I
78 Female 4 Increased CPK 2898 IU/L IV
52 Male 12 Increased CPK 321 IU/L I
67 Male 35 Increased CPK 762 IU/L I
36 Male 4 Increased CPK 404 IU/L I
40 Male 10 Increased CPK 815 IU/L II
69 Female 4 Increased AST 49 IU/L I
41 Male 32 Increased ALT 42 IU/L I
Increased ALP 376 IU/L I
Increased γ-GTP 194 IU/L II
65 Male 23 Decreased Hb 9.7 g/dL -
85 Female 15 Thrombocytopenia 65,000 /mL II
  1. Aspartate aminotransferase, AST; alanine aminotransferase, ALT; creatine phosphokinase, CPK; gamma-glutamyl transferase, γGTP; alkaline phosphatase, ALP; hemoglobin, Hb; The Common Terminology Criteria for Adverse Events, CTCAE
Back to article page

Journal of Pharmaceutical Health Care and Sciences

ISSN: 2055-0294

Contact us